Optimal use of hospital resources and intervention using suPAR for improving prognosis and care for patients with COVID-19

Project description

New test tells COVID-19 patients if they can go home

Assessing the risk factors for severe COVID-19 illness is vital for healthcare providers and hospitals. While this disease is new, it is evident that it can affect anyone. However, the disease can cause symptoms ranging from mild to severe. The EU-funded RISCinCOVID project bring to market the suPARnostic test, which has been developed by Danish company ViroGates. It’s a prognostic inflammatory biomarker that reflects the level of activation of the human immune system. A low suPAR level indicates a good prognosis and supports the decision to discharge the patient. According to ViroGates, their test can identify 22 % more patients that can be sent home without hospitalisation and avoid unnecessary treatments and readmissions.

Fields of science

• social sciences › sociology › demography › mortality
• medical and health sciences › health sciences › infectious disease › RNA virus › coronavirus

Programme(s)

• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020-3
See other projects for this call

Funding Scheme

SME-2b - SME Instrument (grant only and blended finance)

Coordinator

VIROGATES AS

Address

Banevaenget 13/1
3460 Birkerod
Denmark

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU contribution

€ 884 990